Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human ResourcesGlobeNewsWire • 10/01/25
Avalo Reports Second Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewsWire • 08/07/25
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of DirectorsGlobeNewsWire • 06/18/25
Avalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesGlobeNewsWire • 05/12/25
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock UpsideBenzinga • 03/25/25
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/04/25
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsGlobeNewsWire • 11/12/24
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaGlobeNewsWire • 10/08/24
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerGlobeNewsWire • 07/16/24
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis SuppurativaGlobeNewsWire • 07/09/24
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerGlobeNewsWire • 06/24/24
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 05/22/24
Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/13/24